Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Adma Biologics (ADMA)

Adma Biologics (ADMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 401,636
  • Shares Outstanding, K 195,920
  • Annual Sales, $ 80,940 K
  • Annual Income, $ -71,650 K
  • 60-Month Beta 1.07
  • Price/Sales 4.87
  • Price/Cash Flow N/A
  • Price/Book 3.10
Trade ADMA with:

Options Overview Details

View History
  • Implied Volatility 92.68% ( -11.56%)
  • Historical Volatility 88.47%
  • IV Percentile 37%
  • IV Rank 16.55%
  • IV High 371.43% on 05/11/22
  • IV Low 37.41% on 10/15/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 230
  • Volume Avg (30-Day) 312
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 23,717
  • Open Int (30-Day) 22,879

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +46.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.43 +42.66%
on 05/12/22
2.15 -5.34%
on 04/21/22
-0.04 (-1.92%)
since 04/20/22
3-Month
1.38 +47.83%
on 02/24/22
2.15 -5.34%
on 04/21/22
+0.44 (+27.50%)
since 02/18/22
52-Week
1.01 +101.98%
on 10/21/21
2.15 -5.34%
on 04/21/22
+0.28 (+15.91%)
since 05/20/21

Most Recent Stories

More News
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADMA : 2.04 (-0.49%)
CRMD : 3.36 (-3.72%)
Moderna (MRNA) Q1 Earnings and Revenues Top Estimates

Moderna (MRNA) delivered earnings and revenue surprises of 65.64% and 34.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

MRNA : 136.25 (-4.97%)
ADMA : 2.04 (-0.49%)
ADMA Biologics to Report First Quarter 2022 Financial Results on May 11, 2022

Conference Call Scheduled for May 11, 2022 at 4:30 p.m. ET...

ADMA : 2.04 (-0.49%)
ADMA Announces Live Poster Presentation and Symposium on Real-World Experience with ASCENIV™ at CIS 2022

RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end...

ADMA : 2.04 (-0.49%)
ADMA Biologics Announces FDA Approval of Extended Shelf Life for ASCENIV™ & BIVIGAM® from 24 to 36 Months

Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing ...

ADMA : 2.04 (-0.49%)
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

ADMA : 2.04 (-0.49%)
CRMD : 3.36 (-3.72%)
ADMA Biologics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update, Including $175M Debt Refinance with Hayfin Capital Management

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020 Gross Profitability for Full Year 2021 Driven by Greater...

ADMA : 2.04 (-0.49%)
ADMA Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on March 24, 2022

Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET...

ADMA : 2.04 (-0.49%)
ADMA BioCenters Receives FDA Approval for its Fifth Plasma Collection Center, Located in Conyers, GA

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more...

ADMA : 2.04 (-0.49%)
ADMA Biologics Announces Record Preliminary Fourth Quarter and Full Year 2021 Revenues and Provides 2022 Business Update

Fourth Quarter 2021 Preliminary Unaudited Total Revenues of Approximately $26 Million, the Highest Quarterly Revenue for the Company Since Inception Full...

ADMA : 2.04 (-0.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

ADMA Biologics, Inc. is a specialty immune globulin company. It develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. The Company's target patient populations include immune-compromised individuals who suffer from an underlying...

See More

Key Turning Points

3rd Resistance Point 2.16
2nd Resistance Point 2.11
1st Resistance Point 2.08
Last Price 2.04
1st Support Level 2.00
2nd Support Level 1.95
3rd Support Level 1.92

See More

52-Week High 2.15
Last Price 2.04
Fibonacci 61.8% 1.72
Fibonacci 50% 1.58
Fibonacci 38.2% 1.45
52-Week Low 1.01

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar